Related Experiment Video
Updated: May 12, 2026

Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
Mucolipidosis II and III alpha/beta in Brazil: analysis of the GNPTAB gene
G K Cury1, U Matte, O Artigalás
1Post Graduate Program in Medicine, Medical Sciences, Universidade Federal do Rio Grande do Sul, Brazil. gcury1@hotmail.com
Unlabelled:
Mucolipidosis II and III (MLII and MLIII) alpha/beta are rare autosomal recessive lysosomal storage diseases (LSDs) caused by pathogenic variations in the GNPTAB gene. GNPTAB gene codes for the α and β subunits of phosphotransferase, the enzyme responsible for synthesis of the mannose-6-phosphate (M6P) marker that directs lysosomal enzymes to the lysosome.
Objectives:
The objective of this study is to identify sequence variations of the GNPTAB gene in Brazilian patients with MLII and MLIII alpha/beta.
Method:
Sequencing of the GNPTAB gene was performed in samples of gDNA extracted from the peripheral blood of patients with MLII/III diagnosed at a national reference center for LSDs.
Results:
Twelve unrelated patients, from several regions of Brazil, were included in this study. Only one was born of consanguineous parents. All patients were found to carry at least one nonpathogenic variation. Nine causal sequence variations were found: c.242G>T (p.W81L); c.1123C>T (p.R375X); c.1196C>T (p.S399F); c.1208T>C (p.I403T); c.1514G>A (p.C505Y); c.1759C>T (p.R587X); c.2808A>G (p.Y937_M972del, novel mutation); c. 2269_2273delGAAAC (p.E757KfsX2, novel mutation); and c.3503_3504delTC (p.L1168QfsX5). Both pathogenic variations were identified in 8 of 12 patients; in four patients, only one pathogenic variation was identified. Mutation c.3503_3504delTC, located in exon 19, was the most frequent pathogenic variation found (n=11/24 alleles). The deleterious effect of the c.2808A>C mutation on splicing was confirmed by cDNA analysis.
Discussion/Conclusions:
Our findings confirm that the GNPTAB gene presents broad allelic heterogeneity and suggests that, in Brazilian ML II and III patients, screening for mutations should begin at exon 19 of the GNPTAB gene. Further analyses will be conducted on patients in whom both pathogenic mutations have not been found in this study.
Insights
This study identified nine GNPTAB gene variations in Brazilian patients with Mucolipidosis II and III alpha/beta, with exon 19 mutations being most frequent. These findings aid in diagnosing rare lysosomal storage diseases.
Area of Science:
- Genetics
- Biochemistry
- Rare Diseases
Background:
- Mucolipidosis II and III (MLII and MLIII) alpha/beta are rare autosomal recessive lysosomal storage diseases.
- These conditions stem from pathogenic variations in the GNPTAB gene, which encodes subunits of the phosphotransferase enzyme.
- This enzyme is crucial for synthesizing the mannose-6-phosphate marker, essential for lysosomal enzyme targeting.
Purpose of the Study:
- To identify sequence variations in the GNPTAB gene among Brazilian patients diagnosed with MLII and MLIII alpha/beta.
- To contribute to a better understanding of the genetic basis of these rare lysosomal storage diseases in the Brazilian population.
Main Methods:
- Genomic DNA (gDNA) was extracted from the peripheral blood of patients diagnosed with MLII/III.
- The GNPTAB gene was sequenced to identify genetic variations.
- cDNA analysis was used to confirm the deleterious effect of specific mutations on splicing.
Main Results:
- Twelve unrelated Brazilian patients with MLII/III were analyzed.
- Nine distinct causal sequence variations in the GNPTAB gene were identified.
- The mutation c.3503_3504delTC in exon 19 was the most prevalent pathogenic variation, found in 11 out of 24 alleles.
Conclusions:
- The GNPTAB gene exhibits significant allelic heterogeneity in Brazilian patients with MLII and MLIII.
- Genetic screening for MLII and MLIII in Brazil should prioritize mutations in exon 19 of the GNPTAB gene.
- Further investigations are planned for patients with unidentified pathogenic mutations.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Incomplete Dominance
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
